| Filed On | Filing |
|---|---|
| 08 Aug 2025 |
8-K/A: Results of Operations and Financial Condition
The final cohort of the single ascending dose (SAD) part of the Phase 1 AVALON trial initiated, with the SAD data readout expected early in the fourth quarter of 2025; |
| 14 May 2024 |
8-K/A: Results of Operations and Financial Condition; Regulation FD Disclosure
OXFORD, United Kingdom, May 13, 2024 (GLOBE NEWSWIRE) – Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to ... |
| 30 Sep 2022 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On September 20, 2022, Vaccitech plc (the “Company”) filed with the Securities and Exchange Commission a Current Report on Form 8-K (“Original Form 8-K”) disclosing, among other things, that the Board of Directors (the “Board”) of the Co... |
| 24 May 2022 | 8-K/A: Financial Statements and Exhibits |
Loading...
